Get the Stockscreener App
8.32
0.48%
0.02
After Hours:
8.45
0.13
+1.56%
Adicet Bio Inc stock is traded at $8.32, with a volume of 89,151.
It is up +0.48% in the last 24 hours and up +5.57% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
See More
Previous Close:
$8.30
Open:
$8.44
24h Volume:
89,151
Relative Volume:
0.75
Market Cap:
$78.01M
Revenue:
$24.99M
Net Income/Loss:
$-108.83M
P/E Ratio:
-0.5536
EPS:
-15.0286
Net Cash Flow:
$-91.62M
1W Performance:
+15.03%
1M Performance:
+5.57%
6M Performance:
-13.27%
1Y Performance:
-24.85%
1-Day Range:
$8.0312
$8.62
1-Week Range:
$7.23
$8.62
52-Week Range:
$6.01
$17.44
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
8.345 | 77.59M | 24.99M | -108.83M | -91.62M | -15.03 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade - Yahoo Finance
Adicet Bio Shares Halted Ahead of Data Readout That May Steer ACET - Bez Kabli
Adicet Bio (ACET) Shows Resilient Move, Testing Key Resistance After 3.4% GainVerified Analyst Reports - Newser
Adicet Bio (ACET) Q1 2026 Earnings: EPS $-1.88 Beats EstimatesRevenue Beat Analysis - Newser
Adicet Bio, Inc. 2025 10-K/A Annual Report: Controls, Procedures & Internal Control Certifications - Minichart
Adicet Bio (ACET) updates 10-K to confirm effective 2025 controls - Stock Titan
ACET Stock Chart | ADICET BIO INC (NASDAQ:ACET) - ChartMill
Adicet Bio (ACET) Falls -2.34% — Watching $7.12 Support 2026-05-18Market Hype Signals - Newser
Adicet Bio (ACET) price target decreased by 34.28% to 35.53 - MSN
[SCHEDULE 13G/A] Adicet Bio, Inc. Amended Passive Investment Disclosure - Stock Titan
ACET Stock Price, Quote & Chart | ADICET BIO INC (NASDAQ:ACET) - ChartMill
TradingKey - TradingKey
Adicet Bio CEO to discuss cell therapies at Jefferies health conference - Stock Titan
JonesTrading Initiates Adicet Bio(ACET.US) With Buy Rating, Announces Target Price $20 - Moomoo
Press Release Service: Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - CRISPR Medicine News
Adicet Bio (NASDAQ: ACET) cuts Q1 2026 loss while advancing prula-cel and ADI-212 pipeline - Stock Titan
Adicet Bio (Nasdaq: ACET) trims Q1 loss and details prula-cel, ADI-212 plans - Stock Titan
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - New Castle News
Lupus, arthritis and prostate cancer: new cell trials planned by Adicet Bio - Stock Titan
Adicet Bio (NASDAQ:ACET) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
Jefferies Initiates Adicet Bio(ACET.US) With Buy Rating, Announces Target Price $19 - Moomoo
Jefferies initiates Adicet Bio stock with buy rating, $19 target By Investing.com - Investing.com Australia
Jefferies initiates Adicet Bio stock with buy rating, $19 target - Investing.com India
Johnson & Johnson Sells 341,693 Shares of Adicet Bio, Inc. $ACET - MarketBeat
ACET SEC FilingsAdicet Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Adicet Bio (NASDAQ:ACET) Rating Increased to Sell at Wall Street Zen - MarketBeat
Adicet Bio Inc expected to post a loss of $3.11 a shareEarnings Preview - TradingView
ACET Forecast, Price Target & Analyst Ratings | ADICET BIO INC (NASDAQ:ACET) - ChartMill
Adicet Bio (ACET) upgraded to buy: Here's why - MSN
RA Capital (NASDAQ: ACET) exchanges 250K Adicet Bio shares for pre-funded warrant - Stock Titan
Adicet Bio (ACET) sets 2026 virtual meeting, director elections and Say-on-Pay vote - Stock Titan
Adicet Bio Issues Pre-Funded Warrant in Equity Exchange - TipRanks
Adicet Bio (NASDAQ: ACET) issues 250,000-share pre-funded warrant in exchange deal - Stock Titan
Adicet Bio (ACET) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Canaccord Genuity Sticks to Their Buy Rating for Adicet Bio (ACET) - The Globe and Mail
Adicet Bio (ACET) Innovation Pipeline | Adicet Bio Inc. posts wider loss vs estimates, no revenueTrading Community - Cổng thông tin điện tử Tỉnh Sơn La
CCORF Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Adicet Bio Inc. posts wider loss vs estimates, no revenueReal Time Stock Idea Network - Xã Vĩnh Công
Adicet Bio, Inc. (NASDAQ:ACET) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adicet Bio (NASDAQ:ACET) Stock Passes Below Two Hundred Day Moving AverageHere's Why - MarketBeat
RA CAPITAL MANAGEMENT, L.P. Acquires Shares in Adicet Bio Inc - GuruFocus
Orbimed Advisors LLC Reduces Stake in Adicet Bio Inc - GuruFocus
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adicet Bio Inc Stock (ACET) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Feb 19 '26 |
Buy |
7.21 |
74,268 |
535,472 |
1,107,873 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Feb 18 '26 |
Buy |
7.04 |
74,577 |
525,022 |
1,033,605 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 08 '26 |
Sale |
6.42 |
72,939 |
468,082 |
0 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 07 '26 |
Sale |
6.52 |
31,719 |
206,765 |
32,523 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):